These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16208704)

  • 1. Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu.
    Stark AT; Claud S; Kapke A; Lu M; Linden M; Griggs J
    Cancer; 2005 Nov; 104(10):2189-96. PubMed ID: 16208704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women.
    Stark A; Kapke A; Schultz D; Brown R; Linden M; Raju U
    Breast Cancer Res Treat; 2008 Feb; 107(3):405-14. PubMed ID: 17431759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of HER-2/NEU receptor of invasive mammary carcinoma between Caucasian and African American patients in the Detroit metropolitan area. Correlation with overall survival and other prognostic factors.
    Al-Abbadi MA; Washington TA; Saleh HA; Tekyi-Mensah SE; Lucas DR; Briston CA
    Breast Cancer Res Treat; 2006 May; 97(1):3-8. PubMed ID: 16432664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
    Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
    Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
    Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL; Jamehdor MR; Arber JM
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma.
    Choi DH; Shin DB; Lee MH; Lee DW; Dhandapani D; Carter D; King BL; Haffty BG
    Cancer; 2003 Oct; 98(8):1587-95. PubMed ID: 14534873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between HER-2/neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia.
    Kamil M; Yusuf N; Khalid I; Islam R; Biswas M; Hashim H
    Ceylon Med J; 2010 Mar; 55(1):9-13. PubMed ID: 20446534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
    Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
    J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast.
    Boulos F; Farra CG; Saad Aldin EM; Masaad C; Hassoun Y; Fedda F; Doumiati H; Tawil AN; Nasser Z; Nahleh Z; Tfayli A
    J Clin Pathol; 2014 Mar; 67(3):204-9. PubMed ID: 24108431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
    Arafah M
    Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of HER 2/neu gene amplification with immunohistochemistry and other prognostic factors in breast carcinoma.
    Ramadan SS; Yapicier O; Kıhtır S; Erdemır A; Doğan TH; Uskent I; Onat H; Cakmakçi M
    Turk Patoloji Derg; 2011; 27(3):196-203. PubMed ID: 21935868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zonula occludens-1 and Her-2/neu expression in invasive breast carcinoma.
    Bell J; Walsh S; Nusrat A; Cohen C
    Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):125-9. PubMed ID: 12777995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas.
    Seo BK; Pisano ED; Kuzimak CM; Koomen M; Pavic D; Lee Y; Cole EB; Lee J
    Acad Radiol; 2006 Oct; 13(10):1211-8. PubMed ID: 16979070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components.
    Andersson J; Linderholm B; Bergh J; Elmberger G
    Appl Immunohistochem Mol Morphol; 2004 Mar; 12(1):14-20. PubMed ID: 15163013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
    Maru D; Middleton LP; Wang S; Valero V; Sahin A
    Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
    Lateef F; Jamal S; Nasir S
    J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining.
    Mostafa NA; Eissa SS; Belal DM; Shoman SH
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):41-6. PubMed ID: 22099935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics.
    Jones BA; Kasl SV; Howe CL; Lachman M; Dubrow R; Curnen MM; Soler-Vila H; Beeghly A; Duan F; Owens P
    Cancer; 2004 Sep; 101(6):1293-301. PubMed ID: 15368321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.